肾功能不全及OAT抑制对瑞来巴坦联合亚胺培南/西司他丁药代动力学的影响
两项1期开放标签研究分别评估肾功能不全(RI)及有机阴离子转运蛋白(OAT)抑制对瑞来巴坦(REL)联合亚胺培南/西司他丁(IMI)药代动力学的影响。结果显示RI增加REL、亚胺培南及西司他丁的血浆暴露并降低清除率,需按固定比例调整剂量;丙磺舒对REL或亚胺培南的药代动力学无临床意义影响。
要点
- 肾功能不全增加REL、亚胺培南及西司他丁的AUC,且随RI严重程度增加。
- 重度RI时REL和西司他丁的AUC几何均值比可达4.9和5.6,需调整IMI/REL剂量。
- 丙磺舒对REL和亚胺培南的药代动力学无临床意义影响。
核心结论
- 肾功能不全增加REL、亚胺培南及西司他丁的血浆暴露并降低清除率,需按固定比例调整IMI/REL剂量。
- 丙磺舒对REL或亚胺培南的药代动力学无临床意义影响。
研究设计与样本
- 研究PN005为1期开放标签研究,评估REL(125 mg)联合IMI(250 mg)在肾功能不全患者与健康对照中的药代动力学。
- 研究PN019为1期开放标签研究,在健康成人中评估REL(250 mg)和亚胺培南(500 mg,以IMI给药)合用或不合用丙磺舒(1 g,OAT抑制剂)的药代动力学。
主要发现
- REL、亚胺培南和西司他丁的AUC0-∞几何均值比(RI/匹配健康对照)随RI加重而升高:轻度RI分别为1.6(90%CI 1.1-2.4)、1.4(1.1-1.8)和1.6(1.0-2.5),重度RI分别为4.9(3.4-7.0)、2.5(1.9-3.3)和5.6(3.6-8.6)。
- 随着RI加重,三种分析物的血浆清除率和肾清除率均下降,血浆表观终末半衰期延长。
- 丙磺舒联合IMI/REL与单用IMI/REL相比,REL和亚胺培南血浆暴露的几何均值比分别为1.24(1.19-1.28)和1.16(1.13-1.20)。
- 丙磺舒使REL和亚胺培南的肾清除率分别降低25%和31%,并降低两者尿排泄分数(fe)。
- 两项研究中治疗均耐受良好,无严重不良事件或因不良事件停药。
临床怎么用
- 肾功能不全患者使用IMI/REL时需根据肾功能调整剂量(固定比例方案)。
- 丙磺舒等OAT抑制剂对REL或亚胺培南的药代动力学无临床意义影响,合并用药时无需因此调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Two phase 1, open-label studies were conducted to investigate the effect of renal impairment (RI) and organic anion transporter (OAT) inhibition on pharmacokinetics (PK) and safety of relebactam (REL) plus imipenem/cilastatin (IMI). METHODS: Study PN005 evaluated the PK of REL (125 mg) plus IMI (250 mg) in participants with RI vs healthy controls. Study PN019 evaluated the PK of REL (250 mg) and imipenem (500 mg; dosed as IMI) with/without probenecid (1 g; OAT inhibitor) in healthy adults. RESULTS: Geometric mean ratios (RI/healthy matched controls) of area under the concentration-time curve from time 0 to infinity (AUC0-∞ ; 90% confidence interval) for REL, imipenem and cilastatin increased as RI increased from mild (1.6 [1.1, 2.4], 1.4 [1.1, 1.8] and 1.6 [1.0, 2.5], respectively) to severe (4.9 [3.4, 7.0], 2.5 [1.9, 3.3] and 5.6 [3.6, 8.6], respectively). For all 3 analytes, plasma and renal clearance decreased and corresponding plasma apparent terminal half-life increased with increasing RI. Geometric mean ratios ([probenecid+IMI/REL]/[IMI/REL]) of plasma exposure for REL and imipenem were 1.24 (1.19, 1.28) and 1.16 (1.13, 1.20), respectively. The dose fraction excreted (fe) in the urine decreased progressively from mild to severe RI. Probenecid reduced renal clearance of REL and imipenem by 25 and 31%, respectively. Compared with IMI/REL, coadministration of IMI/REL with probenecid yielded lower fe for REL and imipenem. In both studies, treatment was well tolerated; there were no serious adverse events or discontinuations due to adverse events. CONCLUSION: RI increased plasma exposure and similarly decreased clearance of REL, imipenem and cilastatin; IMI/REL dose adjustment (fixed-ratio) will be required for patients with RI. Probenecid had no clinically meaningful impact on the PK of REL or imipenem.
引用
- Bhagunde P, Colon-Gonzalez F, Liu Y, et al. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin. Br J Clin Pharmacol. 2020. PMID: 31856304. doi:10.1111/bcp.14204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。